Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of MY008211A versus eculizumab in complement inhibitor-naive paroxysmal nocturnal hemoglobinuria
CTR20242848Phase 3Completed
- Sponsor
- Meiyue Biotech
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of MY-008 in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Meiyue Biotech. Primary endpoint: Proportion of subjects with sustained hemoglobin level >=120 g/L. Started Aug 2024; status: completed.
02
Drugs
MY-008
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20242848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242848.